February 26, 2018 07:37 AM EST
R&D

Ob­sE­va high­lights a pos­i­tive da­ta point from its PhI­II study of new fer­til­i­ty drug, beats a path to reg­u­la­tors

John Carroll

Editor & Founder

Ob­sE­va $OB­SV re­port­ed that its late-stage tri­al of their lead ther­a­py aimed at pro­mot­ing preg­nan­cies among women with low fer­til­i­ty came through with a boost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times